Tag: Peptide-drug Conjugates
Peptide–drug Conjugate Sudocetaxel Zendusortide Shows Potential as a Single Agent and...
Sudocetaxel zendusortide, also known as TH1902, is as novel, investigational peptide-drug conjugate (PDC) candidate being developed by Canadian biotech Theratechnologies as single agent and in combination with other anticancer therapies. The drug targets tumors that express the sortilin (SORT1) receptor.
Peptide-drug Conjugates: Potent and Selective Miniaturized Conjugates for the Treatment of...
Targeted therapeutics, including antibody-drug conjugates ADCs, designed to link targeted monoclonal antibodies, via a linker, to potent cell-killing payloads, have been a highly successful for creating...
